An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer
MetadataShow full item record
The authors have previously designed, developed, and characterized a novel microencapsulated formulation as a platform for the targeted delivery of therapeutics in an animal model of type 2 diabetes, using the drug probucol (PB). The aim of this study was to optimize PB microcapsules by incorporating the bile acid deoxycholic acid (DCA), which has good permeation-enhancing properties, and to examine its effect on microcapsules’ morphology, rheology, structural and surface characteristics, and excipients’ chemical and thermal compatibilities. Microencapsulation was carried out using a BÜCHI-based microencapsulating system established in the authors’ laboratory. Using the polymer sodium alginate (SA), two microencapsulated formulations were prepared: PB-SA (control) and PB-DCA-SA (test) at a constant ratio (1:30 and 1:3:30, respectively). Complete characterization of the microcapsules was carried out. The incorporation of DCA resulted in better structural and surface characteristics, uniform morphology, and stable chemical and thermal profiles, while size and rheological parameters remained similar to control. In addition, PB-DCA-SA microcapsules showed good excipients’ compatibilities, which were supported by data from differential scanning calorimetry, Fourier transform infrared spectroscopy, scanning electron microscopy, and energy dispersive X-ray studies, suggesting microcapsule stability. Hence, PB-DCA-SA microcapsules have good rheological and compatibility characteristics and may be suitable for the oral delivery of PB in type 2 diabetes.
This article is published under the Open Access publishing model and distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by-nc/3.0/ Please refer to the licence to obtain terms for any further reuse or distribution of this work
Showing items related by title, author, creator and subject.
Alginate-deoxycholic Acid Interaction and Its Impact on Pancreatic ?-Cells and Insulin Secretion and Potential Treatment of Type 1 DiabetesMooranian, Armin; Negrulj, Rebecca; Al-Salami, Hani (2016)© 2016. Springer Science+Business Media New York.Introduction: The secondary bile acid, deoxycholic acid (DCA), has been shown to exert membrane stabilising effects on a pH sensitive delivery system for the oral delivery ...
Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.Mooranian, Armin; Negrulj, R.; Arfuso, Frank; Al-Salami, Hani (2014)Introduction: In a recent study, we confirmed good chemical and physical compatibility of microencapsulated pancreatic β-cells using a novel formulation of low viscosity sodium alginate (LVSA), Poly-L-Ornithine (PLO), and ...
Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine ß-cell Survival and the Inflammatory ResponseMooranian, A.; Negrulj, R.; Al-Salami, Hani (2016)In past studies using hydrogel-polyelectrolyte matrix and different bile acid excipients, we microencapsulated pancreatic ß-cells using various methods, and the microcapsules were mechanically stable, displayed good ...